Floatz logo

Midomafetamine

PTSD

MAPS Europe B.V.Small moleculePhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
81/ 100

Competitive context

22 Active assets in the PTSD cohort.

Asset / SponsorPhaseRating
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Queen's University
Phase 4BBB
Sertraline
Yang I. Pachankis, PhD
Phase 4BB
Paroxetine
University of Washington
Phase 4BB
Cipralex
New York State Psychiatric Institute
Phase 4BB
Methylphenidate
VA Office of Research and Development
Phase 4BB

View all 44 →

Same molecule, other indications

Midomafetamine is also rated in:

post-traumatic stress disorderDormant
B
Indicative ·
62 / 100
View asset →
schizophreniaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →